22 January 2024
22 January 2024
The French company will start the confirmatory trial for its cancer vaccine Tedopi as a second-line lung cancer therapy in Q2 2024.
Jacobio Pharmaceuticals will use the Phase I/II trial results to submit a new drug application to the US Food and Drug Administration (FDA).
Substance-type data contrasted the burden of deaths and increase over time.
The trial randomised around 830 patients to receive either Opdivo monotherapy, Opdivo plus Yervoy, or chemotherapy.
Early initial results from the company’s SOLIS trial detail how the device was able to see a 50% drop in patient pain over the course of a year.
The Clinical Trials Arena team also evaluates assets in ophthalmology, metabolic disorders and oncology.
Lutathera combined with octreotide LAR significantly improved progression-free survival in advanced GEP-NET patients.
Disease progression or mortality risk was reduced by 23% in the Imfinzi group.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
